tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Kezar Life Sciences (KZR), Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kezar Life Sciences (KZRResearch Report), Sutro Biopharma (STROResearch Report) and Relay Therapeutics (RLAYResearch Report) with bullish sentiments.

Kezar Life Sciences (KZR)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kezar Life Sciences today and set a price target of $22.00. The company’s shares closed last Monday at $5.78, close to its 52-week low of $4.31.

According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -40.9% and a 15.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Timber Pharmaceuticals, and Oramed Pharmaceuticals.

Kezar Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $18.33, which is a 209.6% upside from current levels. In a report issued on June 17, Jefferies also assigned a Buy rating to the stock with a $20.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sutro Biopharma (STRO)

Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Sutro Biopharma today and set a price target of $30.00. The company’s shares closed last Monday at $4.33, close to its 52-week low of $3.33.

According to TipRanks.com, Shu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -25.4% and a 20.2% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

Currently, the analyst consensus on Sutro Biopharma is a Strong Buy with an average price target of $23.50.

Relay Therapeutics (RLAY)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics today and set a price target of $47.00. The company’s shares closed last Monday at $18.67.

According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.4% and a 24.9% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.

Relay Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $36.40, a 79.1% upside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $45.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on KZR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed